Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Letter Rheumatology

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Ennio Giulio Favalli et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Patients with lupus with COVID-19: University of Michigan experience

Beth Wallace et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Letter Rheumatology

Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments

Zoe Gendebien et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Rheumatology

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Shintaro Akiyama et al.

Summary: Patients with autoimmune diseases have a higher risk of COVID-19, primarily due to glucocorticoid use. Monotherapy with b/tsDMARDs is associated with a lower risk of hospitalisation and death.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Transplantation

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Alberto Ortiz et al.

Summary: Diabetes, hypertension, and cardiovascular disease have been traditionally considered risk factors for severe COVID-19, but recent studies have found that renal disease, especially dialysis, organ transplantation, and CKD, play a significant role in the mortality risk associated with COVID-19.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry

Milena A. Gianfrancesco et al.

Summary: This study found that African American, Latinx, and Asian patients with rheumatic disease had higher odds of hospitalization due to COVID-19 compared to White patients. These results highlight significant health disparities related to COVID-19 in people with rheumatic diseases.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Meeting Abstract Rheumatology

COMPARISON OF SELF-INJECTION DEVICES FOR ADMINISTERING ANTI-TUMOR NECROSIS FACTOR AGENTS USING THE ORIGINAL QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Y. Hirano et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

Rene Cordtz et al.

Summary: Patients with systemic lupus erythematosus (SLE) have a higher risk of hospitalisation with COVID-19 infection, and the use of hydroxychloroquine treatment may reduce the risk of hospitalisation.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients

Isabela Maria Bertoglio et al.

Summary: This study reveals that patients with SLE hospitalized with COVID-19 have significantly higher risks of death and poor outcomes compared to patients without comorbidities and those with other comorbidities.

ACR OPEN RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases

Rebecca Hasseli et al.

Summary: The study found that factors such as age, cardiovascular disease, interstitial lung disease/chronic obstructive pulmonary disease, chronic kidney disease, and long-term use of glucocorticoids were associated with an increased risk of hospitalization for COVID-19 in patients with inflammatory rheumatic and musculoskeletal diseases.

RMD OPEN (2021)

添加到收藏夹

Article Rheumatology

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study

April Jorge et al.

Summary: Severe COVID-19 outcomes have shown improvement over time for patients with rheumatic and musculoskeletal diseases, indicating potential progress in treatment and supportive care.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology